The estimated Net Worth of Christopher Pechock is at least $1.71 Billion dollars as of 5 March 2020. Mr. Pechock owns over 82,645 units of MYOS RENS Technology stock worth over $343,200 and over the last 20 years he sold MYOS stock worth over $1,705,890,684. In addition, he makes $0 as Independent Director at MYOS RENS Technology.
Christopher has made over 5 trades of the MYOS RENS Technology stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 82,645 units of MYOS stock worth $100,000 on 5 March 2020.
The largest trade he's ever made was selling 56,979,062 units of MYOS RENS Technology stock on 6 August 2007 worth over $1,381,742,254. On average, Christopher trades about 6,479,092 units every 500 days since 2005. As of 5 March 2020 he still owns at least 339,802 units of MYOS RENS Technology stock.
You can see the complete history of Mr. Pechock stock trades at the bottom of the page.
Christopher R. Pechock (Chris) is Independent Director of the Company. Mr. Pechock was a partner at Matlin Patterson Global Advisers, a global alternative asset manager, since its inception in July 2002 through September 2017. From November 1998 to July 2002, Mr. Pechock served as a member of the Global Distressed Securities Group Credit Suisse (NYSE:CS). From January 1997 to October 1998, Mr. Pechock served as a Portfolio Manager and Research Analyst at Turnberry Capital Management, L.P. Prior to that, Mr. Pechock served as a Portfolio Manager at Eos Partners, L.P. (February 1996 to December 1996), a Vice President and high yield analyst at PaineWebber Inc. (May 1993 to January 1996) and an analyst in risk arbitrage at Wertheim Schroder & Co., Incorporated (August 1987 to April 1991). Mr. Pechock received a BA in Economics from the University of Pennsylvania and an MBA from the Columbia University Graduate School of Business.
Christopher Pechock is 55, he's been the Independent Director of MYOS RENS Technology since 2014. There are 6 older and no younger executives at MYOS RENS Technology. The oldest executive at MYOS RENS Technology, Inc. is Christopher Dewey, 75, who is the Independent Director.
Christopher's mailing address filed with the SEC is C/O MYOS RENS TECHNOLOGY INC., 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS, NJ, 07927.
Over the last 12 years, insiders at MYOS RENS Technology have traded over $0 worth of MYOS RENS Technology stock and bought 2,115,845 units worth $2,654,259 . The most active insiders traders include David J Matlin, Christopher Pechock, and Joseph Mannello. On average, MYOS RENS Technology executives and independent directors trade stock every 78 days with the average trade being worth of $59,361. The most recent stock trade was executed by Joseph Mannello on 31 March 2020, trading 16,529 units of MYOS stock currently worth $16,694.
MYOS RENS Technology, Inc. operates as a nutrition company, develops and markets products that improve muscle health and performance. Its primary product is Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk, intended to increase lean muscle mass, size, and strength. The company was founded on April 11, 2007 and is headquartered in Cedar Knolls, NJ.
MYOS RENS Technology executives and other stock owners filed with the SEC include: